Our EP300-ZNF384 patients cluster in the AYA range and have reduced CD10 surface expression and up-regulated CD33 expression in common with previous reports.3,5 The EP300-ZNF384 subgroup showed improved outcome compared to other pre-B-ALL patients studied, and concurs with a Japanese cohort where ZNF384 fusions have better survival outcomes than Ph-like ALL in AYA.3 This report contributes to a better overview of the incidence of EP300-ZNF384 patients and the prognostic significance of ZNF384 lesions deserves further study and validation. The gene discussed is EP300; the disease is acute lymphoblastic leukemia.